- The Hong Kong stock market's healthcare sector is accelerating the commercialization of weight loss pipelines and medical AI, with leading companies repurchasing shares worth over hundreds of millions of Hong Kong dollars to stabilize market expectations.
- Hansoh Pharma has initiated a Phase III trial for its oral GLP-1/GIP project and formed a collaboration worth over $1 billion with Bristol-Myers Squibb, while other firms like Innovent Biologics are expanding revenue through new drug approvals.
- Despite challenges such as shareholder dissent on capital allocation, key companies are countering macro uncertainties through overseas clinical registrations and intensive buybacks, focusing capital on firms with substantive commercialization progress.
